Joenja (leniolisib) prior authorization
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
Defines UnitedHealthcare Pharmacy prior authorization and reauthorization requirements for Joenja (leniolisib) for treatment of activated phosphoinositide 3-kinase delta (APDS) in patients 12 years and older.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Authorization
Covered when ALL of the following are met
Authorization will be issued for 12 months
Reauthorization
Covered when ALL of the following are met
Authorization will be issued for 12 months
Coverage for Joenja (leniolisib) is limited to patients who meet the policy's age requirement. Patients < 12 years of age are not eligible for coverage under this policy; coverage is available only for patients who are 12 years of age or older.
Initial Therapy
Initial Therapy
Covered when ALL of the following are met
Authorization will be issued for 12 months
Reauthorization / Continuation Therapy
Reauthorization
Reauthorization requirements
Authorization will be issued for 12 months
Provider Actions and Operational Notes
Prior authorization required; initial approval for APDS patients ≥12 years
Prior authorization is required. Initial approvals are granted only when both criteria are met: (a) a diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS) and (b) the patient is 12 years of age or older. Authorizations are issued for 12 months.
No step therapy; supply limits and automated approvals may apply
No step therapy requirements are specified in this policy. Supply limits may be in place, and UnitedHealthcare may use automated approval and re-approval processes (for example, based on prior claim/medication history, diagnosis codes, or claim logic) depending on program/therapeutic class.
Document diagnosis, age; reauthorization requires clinical response evidence
Document the patient’s diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS) and the patient’s age to support initial authorization. For reauthorization, provide documentation of a positive clinical response to Joenja therapy. Note that state mandates, federal requirements, and the member’s benefit plan may affect documentation requirements and coverage.
Denial risk if no APDS diagnosis or patient <12 years
Requests lacking documentation of an APDS diagnosis or for patients younger than 12 years may be denied — coverage is limited to patients 12 years and older per the policy.
Quantity Limits
Definitions
Background
Joenja (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). Under this policy, prior authorization is required and initial approval is granted when the patient has a documented diagnosis of APDS and is 12 years of age or older. Authorizations are issued for a period of 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.